Effector Therapeutics Inc (EFTR) — Capital Reinvestment Ratio

Latest as of December 2020: 0.01x

Effector Therapeutics Inc (EFTR) has a Capital Reinvestment Ratio of 0.01x as of December 2020, meaning it reinvests 0% of its operating cash flow ($13.84 Million) in capital expenditures ($154.00K). Check tangible equity quality of Effector Therapeutics Inc to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.01x
Capex / Operating Cash Flow

Operating Cash Flow

$13.84 Million
USD

Capital Expenditures

$154.00K
USD

Data as of

Dec 2020
Most recent filing

Effector Therapeutics Inc Capital Reinvestment Ratio (2020–2020)

This chart tracks Effector Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see EFTR cash flow metrics.

Annual Capital Reinvestment Ratio for Effector Therapeutics Inc (2020–2020)

Year-by-year Capital Reinvestment Ratio for Effector Therapeutics Inc from 2020 to 2020. See how much free cash does Effector Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2020 0.01x $13.84 Million $154.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow